By Bahar YukselIs it the new gold mine for endometriosis: oral GnRH antagonists
By Bahar Yuksel
Progestins and combined oral contraceptive pills are the first step hormonal options for women with endometriosis. But the more the use expands the more cases are seen with resistance to progestins. This gave birth to a need for different therapeutic…
Key Points Lay Summary
By Hale Goksever CelikEndometriosis and female pelvic pain in all aspects
By Hale Goksever Celik
Endometriosis is defined as the localization of endometrial glandular and stromal tissue outside the uterine cavity. The prevalence of the disease ranges between 6-10% in reproductive-aged women. However, endometriosis is more frequently encountered in women with chronic pelvic pain and…
Key Points Lay Summary
By Özge ÖzkayaThe use of Elagolix in Women with Liver and Kidney Impairments
By Özge Özkaya
Elagolix may be used in women with moderate liver impairment, when necessary, for up to six months at a dose of 150 mg a day, according to a study published in the scientific journal Clinical Pharmacology in Drug Development. The…
Key Points Lay Summary
FDA Approves Endometriosis Pain Treatment
By Özge Özkaya
The U.S. Food and Drug Administration (FDA) approved a new medication for the treatment of moderate to severe pain associated with endometriosis, making it the first treatment to be approved in 10 years. The decision was announced in the Journal…
Key Points Lay Summary
By Murat OsmanEmerging medical treatments for endometriosis
By Murat Osman
Endometriosis is a disease whereby uterine tissue grows outside the walls of the uterus to the surfaces of other tissues in the body. It is a chronic disease and relies upon estrogen to grow and survive. Current medical therapies take…
Key Points Lay Summary
By Kasthuri NairEFA Medical Conference 2017: "Hormone and Cytokine Sensitivity in Endometriosis" Presentation by Dr. Robert Taylor
By Kasthuri Nair
The first presenter of the “Estrogen from Inflammation to Cancer: A Distant Link?” section of EFA 2017 Medical Conference was Dr. Robert Taylor from Wake Forest University Health Sciences. Dr. Taylor’s presentation was titled “Hormone and Cytokine Sensitivity in Endometriosis.”…
Key Points Lay Summary
By Yu YuTreatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
By Yu Yu
Taylor et al. presented an exciting recent study in The New England Journal of Medicine. This article reported the results from a multicentre, double-blind, randomized, placebo-controlled phase 3 trials of elagolix for the treatment of endometriosis-associated pain. As women with…
Key Points Lay Summary
Elagolix (ABT-620) for endometriosis pain?
By Yu Yu
Elagolix is an orally active gonadotropin-releasing hormone antagonist that has just recently completed Phase 3 clinical trial for endometriosis-associated pain (NCT01931670). The review article by Alessandro et al in Archives of Gynecology and Obstetrics summarized the current research findings on…
Key Points Lay Summary